Ubben Takes Big Profit From Valeant Pharmaceuticals International Inc. (VRX) Stake, Sells Over 4.3 Million Shares

Additionally, Valeant Pharmaceuticals International has recently announced the appointment of former McKinsey & Co employee, Robert Rosiello, as the next Chief Financial Officer (CFO) of the firm. In late April, the former CFO of Valeant, Howard Schiller, stepped down from the position after a period of exorbitant growth for the company. However, the tremendous expertise of the newly-assigned CFO in healthcare and M&A in particular will be of great value for the company. It is uncertain whether Robert Rosiello will follow the same growth-by-acquisition plan that has been previously employed, but nevertheless, it should be expected that Valeant will most probably benefit from the expertise, intellect and work ethic of the new CFO.

Let’s now go over Valeant’s financial performance delivered during the most recent fiscal quarter. Unquestionably, the company managed to deliver quite strong first quarter financial results. The revenues of the company reached a figure of $2.19 billion in the period, which marks an increase of 15% year-over-year. Valeant also reported a profit of $70.4 million during the quarter. At the same time, the company expects to generate revenues in the range of $2.96 billion to $3.08 billion for the second quarter of the current year, which is a clear sign that Valeant is on the right path. In spite of the fact that the stock has already achieved an immense gain since the beginning of the current year, some analysts believe that Valeant’s shares might reach a price level of $400 per share, which theoretically represents a 74% upside. Within our database of over 700 hedge funds, the largest shareholder in Valeant Pharmaceuticals International Inc. (NYSE:VRX) is Glenn Greenberg’s Brave Warrior Capital with 5.88 million shares valued at $1.17 billion as of March 31, 2015.

Disclosure: None